Auteri M, Zizzo MG, Serio R GABA and GABA receptors in the gastrointestinal tract: from motility to inflammation. Pharmacol Res. 2015 Mar;93:11-21. doi: 10.1016/j.phrs.2014.12.001. Epub 2014 Dec 17.
Belkaid Y, Hand TW Role of the microbiota in immunity and inflammation. Cell. 2014 Mar 27;157(1):121-41. doi: 10.1016/j.cell.2014.03.011.
Dhakal R, Bajpai VK, Baek KH Production of gaba (gamma - Aminobutyric acid) by microorganisms: a review. Braz J Microbiol. 2012 Oct;43(4):1230-41. doi: 10.1590/S1517-83822012000400001. Epub 2012 Jun 1.
Dinan TG, Cryan JF Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration. J Physiol. 2017 Jan 15;595(2):489-503. doi: 10.1113/JP273106. Epub 2016 Dec 4.
Flux MC, Lowry CA Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience. Neurobiol Dis. 2020 Feb;135:104578. doi: 10.1016/j.nbd.2019.104578. Epub 2019 Aug 24.
Fogaca MV, Duman RS Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions. Front Cell Neurosci. 2019 Mar 12;13:87. doi: 10.3389/fncel.2019.00087. eCollection 2019.
Hausser-Kinzel S, Weber MS The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders. Front Immunol. 2019 Feb 8;10:201. doi: 10.3389/fimmu.2019.00201. eCollection 2019.
Kalueff AV, Nutt DJ Role of GABA in anxiety and depression. Depress Anxiety. 2007;24(7):495-517. doi: 10.1002/da.20262.
Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci. 2015 Oct 14;9:392. doi: 10.3389/fncel.2015.00392. eCollection 2015.
Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1044-53. doi: 10.1016/j.pnpbp.2007.03.004. Epub 2007 Mar 13.
Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444-52. doi: 10.1212/wnl.33.11.1444.
Lassmann H, Bradl M Multiple sclerosis: experimental models and reality. Acta Neuropathol. 2017 Feb;133(2):223-244. doi: 10.1007/s00401-016-1631-4. Epub 2016 Oct 20.
Lee CH, Giuliani F The Role of Inflammation in Depression and Fatigue. Front Immunol. 2019 Jul 19;10:1696. doi: 10.3389/fimmu.2019.01696. eCollection 2019.
Liu Y, Tang X Depressive Syndromes in Autoimmune Disorders of the Nervous System: Prevalence, Etiology, and Influence. Front Psychiatry. 2018 Sep 25;9:451. doi: 10.3389/fpsyt.2018.00451. eCollection 2018.
Luscher B, Shen Q, Sahir N The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011 Apr;16(4):383-406. doi: 10.1038/mp.2010.120. Epub 2010 Nov 16.
McGovern AS, Hamlin AS, Winter G A review of the antimicrobial side of antidepressants and its putative implications on the gut microbiome. Aust N Z J Psychiatry. 2019 Dec;53(12):1151-1166. doi: 10.1177/0004867419877954. Epub 2019 Sep 26.
Miller AH, Maletic V, Raison CL Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009 May 1;65(9):732-41. doi: 10.1016/j.biopsych.2008.11.029. Epub 2009 Jan 15.
Pehrson AL, Sanchez C Altered gamma-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants. Drug Des Devel Ther. 2015 Jan 19;9:603-24. doi: 10.2147/DDDT.S62912. eCollection 2015.
Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem. 2006 Feb 1;78(3):779-87. doi: 10.1021/ac051437y.
van den Hoogen WJ, Laman JD, 't Hart BA Modulation of Multiple Sclerosis and Its Animal Model Experimental Autoimmune Encephalomyelitis by Food and Gut Microbiota. Front Immunol. 2017 Sep 5;8:1081. doi: 10.3389/fimmu.2017.01081. eCollection 2017.
Wallace CJK, Milev R The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry. 2017 Feb 20;16:14. doi: 10.1186/s12991-017-0138-2. eCollection 2017. Erratum In: Ann Gen Psychiatry. 2017 Mar 7;16:18.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.